← All trials
NCT04510207
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 16, 2020
- Primary completion
- Mar 16, 2021
- Completion date
- Sep 16, 2021
- First posted
- Aug 12, 2020
- Last posted
- Oct 30, 2020
- Enrollment
- 45000
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- China National Biotec Group Co., LtdLead sponsor
- Wuhan Institute of Biological Products Co., LtdCollaborator
- Beijing Tiantan Bio Co., LtdCollaborator
- Beijing Tiantan Bio Co., LtdCollaborator
- Abu Dhabi Health Services CompanyCollaborator
- G42 Healthcare companyStudy director
- G42 Healthcare companyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.